Latest News about REGN
Recent news which mentions REGN
From Benzinga
Could This New Indication Create a Blockbuster for Pfizer?
February 05, 2022
From Motley Fool
This Will Put a Big Dent in Eli Lilly's and Regeneron's Sales This Year
February 04, 2022
From Motley Fool
COVID-19 treatments raked in billions of dollars in 2021. How will they do this year?
February 04, 2022
From MarketWatch
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales
February 04, 2022
Tickers
REGN
From Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
From Benzinga
Earnings Scheduled For February 4, 2022
February 04, 2022
From Benzinga
What This FDA News Could Mean for Pfizer
February 01, 2022
From Motley Fool
Should Investors Sell Eli Lilly After This Recent Regulatory News?
February 01, 2022
From Motley Fool
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
From Benzinga
3 Biotech Stocks That Could Boom or Bust in Q1
February 01, 2022
From InvestorPlace
5 Things To Expect This Week
January 31, 2022
From InvestorPlace
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
From Benzinga
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
January 31, 2022
From Benzinga
Market corrections are good buying opportunities, says Goldman Sachs — but only when this happens
January 31, 2022
From MarketWatch
A Deep Dive Into the Video Game Industry
January 29, 2022
From Motley Fool
Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?
January 29, 2022
From Motley Fool
From Benzinga
From Benzinga
From MarketWatch
Pfizer and BioNTech launch study of omicron vaccine, and FDA halts use of two COVID antibody treatments
January 25, 2022
From MarketWatch
A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting
January 25, 2022
From Benzinga
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
January 24, 2022
From Benzinga
Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
January 24, 2022
From Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.